Skip to main content

Longitudinal Integrative Models for Online Relapse Detection

Project description

Harnessing statistical analyses to improve multiple myeloma outcomes

Multiple myeloma is a type of bone marrow cancer affecting white blood cells called plasma cells. These cells help the body fight infections by making antibodies that recognise and attack invaders. In multiple myeloma, cancer cells that produce abnormal proteins accumulate in the bone marrow, destroying bone and displacing healthy blood cells. The cancer can affect multiple areas of the body, including the spine, skull, pelvis and ribs, hence the term 'multiple myeloma'. The relapse rate is 100 % – it is not curable but can go into remission. However, treatments are available. The EU-funded LIMORD project is developing a statistical tool that will be incorporated into a software package for clinical use, enabling more accurate patient classification, earlier relapse detection and better prognosis estimation. The tool will support personalised medicine and improve patient outcomes.

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 125 645,28
Address
Rue Michel Ange 3
75794 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 125 645,28

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

THE AUSTRALIAN NATIONAL UNIVERSITY
Australia
Net EU contribution
€ 0,00
Address
Liversidge Street 1 Building 67c
0200 Canberra

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00